Introduction {#Sec1}
============

In stereotactic radiosurgery (SRS) for brain metastases (BM), the dose is generally prescribed according to a risk-adapted approach depending on the size of the planning target volume (PTV): for smaller PTVs higher SRS doses are prescribed than for larger PTVs with the aim to limit toxicity to acceptable levels in large BM \[[@CR1]\]. In Radiation Therapy Oncology Group (RTOG) study 90-05, the maximum tolerated single-fraction dose for BM with a diameter \>3 cm was 15 Gy, as a higher dose of 18 Gy was associated with an unacceptably high rate of severe central nervous system toxicity of 50% \[[@CR3]\]. Recently, consensus was reached within the Netherlands for SRS dose prescriptions: a single dose of 24 Gy is prescribed to PTV sizes \<1 cm^3^ and the dose level is stepwise decreased to 21, 18 and 15 Gy for PTV sizes between 1--10 cm^3^, between 10--20 cm^3^, and \>20 cm^3^, respectively. In clinical practice, SRS is used for inoperable BM up to a diameter of 4 cm. The consequence of this PTV size-based dose prescription protocol is a 12-month local tumor control probability (TCP) of about 86% in small BM and a TCP of around 40% in large BM \[[@CR4], [@CR5]\]. Given the low TCP for large BM and taking into account that patients with large BM are often medically inoperable, there is a clear need for improvement of SRS in these patients, but not at the cost of an unacceptably high risk of toxicity. This is currently being investigated in phase I studies \[[@CR6]\]. An alternative to PTV size-based dose prescription is isotoxic dose prescription (IDP) \[[@CR7]--[@CR13]\]. The quintessence of this strategy is that the normal tissue tolerance level is always respected and used as a base for dose prescription. Thereby the risk of radionecrosis is kept low. The dose in the tumor is increased to the highest dose that is technically achievable and thereby maximizing the TCP while simultaneously respecting the normal tissue constraint. The IDP concept is different from the PTV size-based dose prescription approach, where fixed prescription doses are used that solely depend on the size of the target volume and for large BM do not respect the predefined dose--volume constraint for normal tissue. From previous studies of single-fraction SRS for BM, it is known that the risk of radionecrosis increases rapidly if the volume of the surrounding healthy brain tissue receiving at least 12 Gy is greater than 10 cm^3^ (that is, V~12Gy~ \> 10 cm^3^) \[[@CR14]--[@CR16]\]. Apart from being dependent on the tumor prescription dose, the V~12Gy~ also depends on the gross tumor volume-to-planning target-volume (GTV-PTV) margin used as well as on the beam arrangement (i. e., coplanar vs non-coplanar) that affect the degree of dose conformity and the steepness of the dose gradient at the outer rim of the PTV \[[@CR17]\].

In this study, the hypothesis is tested that through IDP the predicted TCP in large BM up to 4 cm diameter can be improved from the disappointing low level of 42% that is obtained with a standard single SRS dose of 15 Gy while simultaneously respecting an acceptably low normal tissue complication probability (NTCP). Furthermore, the effects of GTV volume, different GTV-PTV margins, and beam arrangements on the predicted TCP are systematically assessed \[[@CR4], [@CR18], [@CR19]\]. Both single-fraction and fractionated stereotactic radiotherapy (FSRS) IDP schemes are considered to assess the effect of fractionation.

Materials and methods {#Sec2}
=====================

This study comprises three phases. First, the potential to increase TCP under isotoxic conditions is investigated for single-fraction, three-fraction and five-fraction IDP schemes, with artificial BM having spherical GTV shapes of different diameters (0.5--4.0 cm, with stepwise increasing diameter of 0.5 cm, Table [1](#Tab1){ref-type="table"} for treatment plan characteristics). This allows us to systematically derive empirical relationships between the GTV size and the maximum achievable predicted TCP as a function of the GTV-PTV margin and the beam arrangement. Second, these results are compared against clinically delivered SRS treatment plans in 46 patients with realistically shaped GTVs.Table 1Characteristics of 48 SRS plans for artificially contoured BMCoplanar VMAT beam arrangementNon-coplanar VMAT beam arrangementDiameter GTV/GTV -PTV margin (cm)D~max~ (%) in PTVD~mean~ (%) in PTVRTOG CIPaddick GID~max~ (%) in PTVD~mean~ (%) in PTVRTOG CIPaddick GI*0.5/0*101902.014.8103901.514.6*0.5/0.1*123982.59.7128981.29.2*0.5/0.2*135991.27.91331001.16.1*1.0/0*126971.16.9111911.17.2*1.0/0.1*1271031.25.71401041.14.7*1.0/0.2*118991.14.6125981.04.3*1.5/0*1271011.14.5118961.04.3*1.5/0.1*1211031.14.01351071.03.6*1.5/0.2*1181001.04.01451061.03.2*2.0/0*1161001.03.9112961.03.4*2.0/0.1*1301091.13.71321081.03.2*2.0/0.2*1201011.03.61301051.03.0*2.5/0*1221031.03.7106941.02.6*2.5/0.1*1241081.13.51251041.02.9*2.5/0.2*1241041.03.41311081.02.8*3.0/0*1261021.03.5113971.02.8*3.0/0.1*1261081.13.31241061.02.7*3.0/0.2*1261061.03.31281061.02.7*3.5/0*1311021.03.3109961.02.7*3.5/0.1*1241071.13.21221051.02.6*3.5/0.2*1281071.03.21271071.02.6*4.0/0*1351021.03.1112971.02.6*4.0/0.1*1211041.13.01261051.02.5*4.0/0.2*1341071.03.11391131.02.6*VMAT* volumetric modulated arc therapy, *GTV* gross tumor volume, *PTV* planning target volume, *RTOG CI* Radiation Therapy Oncology Group Conformity Index, *Paddick GI* Paddick gradient index, *BM* brain metastasis, *SRS* stereotactic radiosurgery

Nominal treatment plans: target-volume definition and treatment-planning technique {#Sec3}
----------------------------------------------------------------------------------

A computed tomography (CT) scan (Siemens Somatom Sensation Open, Erlangen, Germany) of an anonymized patient treated with SRS for BM was used to design nominal treatment plans having a dose prescription according to the Dutch consensus guidelines. The head and neck region was imaged until the claviculae with a slice thickness of 1 mm. In the treatment-planning system (Eclipse version 11.0.42, Varian, Palo Alto, CA, USA), 8 perfectly spherical GTVs with diameters ranging from 0.5 to 4.0 cm in steps of 0.5 cm were contoured in the right parietal lobe so that the brain stem and optic system did not overlap with the PTV. For each GTV, a PTV was created by isotropic expansion with a margin of 0, 1, and 2 mm. The dose prescription based on PTV size was a single fraction of 24, 21, 18, and 15 Gy for PTV sizes \<1, 1--10, 10--20 cm^3^, and 20--65 cm^3^. With the prescribed dose, 99% of the PTV was covered, while having a steep dose gradient outside the PTV for brain sparing and allowing large dose inhomogeneity within the PTV. Per PTV, two 10 MV photon-based volumetric modulated arc therapy (VMAT, calculation grid size 1 × 1 × 1 mm^3^) plans were made by the same treatment planner, one with two overlapping coplanar arcs at a couch angle of 0° and one with three non-coplanar arcs having a couch angle of 0°, 45°, and 315° and a collimator angle of 30° or 330º. In total, 48 treatment plans were generated (Table [1](#Tab1){ref-type="table"}). For each treatment plan, the V~12Gy~ of the healthy brain minus the GTV was determined.

Renormalized treatment plans: IDP based on normal tissue dose constraint {#Sec4}
------------------------------------------------------------------------

For single-fraction IDP-based dose prescription, the nominal treatment plans with spherical GTVs were renormalized (by altering the monitor units) such that V~12Gy~ = 10 cm^3^ for the healthy brain minus the GTV. The corresponding IDP dose levels for each of the 48 treatment plans were assessed for further analysis. The same procedure was used for the five-fraction IDP scheme, but a V~20Gy~ = 20 cm^3^ constraint for the healthy brain minus the GTV was used instead \[[@CR20]\]. For three-fraction IDP a V~19.2~ ~Gy~ = 10 cm^3^ was used as a normal tissue constraint. This constraint was recalculated from the V~12Gy~ = 10 cm^3^ using the linear quadratic model using an α/β ratio for brain tissue of 3. The predicted TCP was calculated from the IDP prescription dose by using a dose--response model that was statistically fitted to the data points of Wiggenraad et al. \[[@CR4]\] (see Appendix). For calculation, plotting, and rescaling of the dose--volume histograms (DVHs), in-house developed MATLAB scripts (Version 8.5; The MathWorks, Inc., Natick, MA, USA) were used.

Validation of IDP results in clinically delivered SRS plans {#Sec5}
-----------------------------------------------------------

Since in clinical practice the GTVs of BM are not perfectly spherical and the plan quality may slightly vary due to inter- and intratreatment planner differences, we compared the IDP dose levels obtained from the 48 treatment plans with perfectly spherical GTVs to those of clinical treatment plans comprising 46 consecutive patients who had been treated with SRS for a single BM at our institution between January 2013 and June 2014 with a dose of 15--24 Gy in 1--3 fractions. Patients had been considered eligible for SRS if they had a maximum of four BM from metastasized solid primary tumors (e. g., non-small cell lung cancer, breast cancer, colorectal cancer, melanoma, and bladder cancer) at the pretreatment contrast-enhanced magnetic resonance imaging (MRI) scan, a Karnofsky performance status of 70 or more, and extracranial treatment options. The selected cohort was identified from a database containing all patients who had been treated with SRS for newly diagnosed BM in our institution. Prior to treatment, a gadolinium contrast-enhanced MRI scan (3D T~1~-weighted sequence on a 1.5 T Ingenia/Intera or 3 T Achieva scanner, Philips Medical Systems, Eindhoven, Netherlands) was made with a slice thickness of 1 mm. Patients had been immobilized with a frameless mask and underwent an iodide contrast-enhanced CT scan (Siemens Somatom Sensation Open, Erlangen, Germany) with a slice thickness of 1 mm. For treatment-planning purposes, the MRI scan had been rigidly co-registered with the CT scan in Eclipse (Varian, Palo Alto, CA, USA). The BM had been delineated as GTV contours on the MRI scan and visually checked on the CT scan thereafter. A GTV-PTV margin of 2 mm had been applied. A VMAT (RapidArc) technique with 10 MV coplanar beams had been used to design the dose distribution for delivery with a TrueBeam STX linear accelerator (Varian, Palo Alto, CA, USA). To derive the IDP dose levels for our study, these treatment plans were renormalized such that the constraints V~12Gy~ = 10 cm^3^, V~19.2~ ~Gy~ = 10 cm^3^, and V~20Gy~ = 20 cm^3^ were satisfied for the single-, three-, and five-fraction schemes, respectively.

Statistical methods {#Sec6}
-------------------

The Pearson's chi-squared test was used as a measure of fit between the IDP dose levels of the spherical GTVs and those of the non-spherical GTVs of the clinical plans. The difference between the coefficients of both exponential decay models was zero.

Results {#Sec7}
=======

The application of a non-zero GTV-PTV margin results in an increase in the PTV size and may hence influence the PTV size-based dose prescription and thereby the therapeutic ratio. As indicated by the change in symbol shapes in Fig. [1](#Fig1){ref-type="fig"}, applying a GTV-PTV margin of 1 mm instead of 0 mm resulted in lowering the nominal prescription dose from 21 to 18 Gy for a GTV diameter of 2.5 cm, while for the other 7 GTV diameters, the prescribed dose did not change. Applying a GTV-PTV margin of 2 mm instead of 0 mm resulted in decreasing the nominal prescription dose from 24 to 21 Gy, from 21 to 18 Gy, and from 18 to 15 Gy for GTV diameters of 1.0, 2.5, and 3.0 cm, respectively, while for the other 5 GTV diameters, the prescribed dose remained the same.Fig. 1Commonly used risk-adapted dose prescription based on PTV size and its effect on exceeding the normal tissue constraint for radionecrosis risk V~12Gy~ = 10 cm^3^. The V~12Gy~ as function of GTV size is presented for different GTV-PTV margins and beam arrangements. Legend: *GTV* gross tumor volume, *PTV* planning target volume, *V*~12Gy~ volume of healthy brain tissue which is irradiated to 12 Gray or more. The GTV-PTV margin: 0 mm (**a**), 1 mm (**b**), and 2 mm (**c**). The open and filled symbols represent non-coplanar and coplanar beams, respectively. The single-fraction PTV size-based dose prescription: 24 Gy (*triangle*), 21 Gy (*square*), 18 Gy (*diamond*), and 15 Gy (*circle*)

Applying a non-zero GTV-PTV margin also results in an increase of the dose absorbed in uninvolved healthy brain tissue and therefore affects the NTCP and therapeutic ratio. When the single-fraction PTV size-based dose prescription protocol is applied to the 8 perfectly spherical GTVs, V~12Gy~ shows a clear tendency to increase with increasing GTV size and increasing GTV-PTV margin and is generally lower for the non-coplanar beam arrangement than for the coplanar beams (Fig. [1](#Fig1){ref-type="fig"}). From this figure, it is evident that for GTV diameters \>2 cm, V~12Gy~ exceeds the 10 cm^3^ constraint level irrespective of the GTV-PTV margin or the beam arrangement. Furthermore, this figure shows that for a GTV diameter of 4 cm, V~12Gy~ is reduced from 33 cm^3^ to 13 cm^3^ in case a GTV-PTV margin of 0 mm instead of 2 mm is used in combination with non-coplanar beams instead of coplanar beams.

To test whether the single-fraction IDP dose levels derived for the spherical GTVs apply to the non-spherical GTVs of the clinical treatment plans, an empirical relationship between the PTV size of the spherical GTVs and the single-fraction IDP dose level was derived by fitting an exponential decay model to the data of the coplanar beam arrangement with a GTV-PTV margin of 2 mm (Fig. [2](#Fig2){ref-type="fig"}). The same was done for the IDP dose of the 46 clinical treatment plans with non-spherical PTVs. It could be shown that there is no statistically significant difference between these fits. The median (±SD) IDP dose difference between the spherical GTVs of the artificial treatment plans and the non-spherical GTVs of the clinical treatment plans was 0.25 ± 1.70 Gy and ranged from −3.92 to 2.16 Gy.Fig. 2Clinical validation of plan quality of the *in silico* SRS treatment plans with artificially contoured BM compared to clinically delivered SRS treatment plans in BM patients. A comparison of the single-fraction IDP dose level with V~12Gy~ = 10 cm^3^ for coplanar beam arrangement and GTV-PTV margin of 2 mm between perfectly spherical GTVs (*filled dots*) and non-spherical GTVs of clinical plans (*open dots*). Legend: *Gy* Gray, *GTV* gross tumor volume, *PTV* planning target volume, *SRS* stereotactic radiosurgery, *BM* brain metastases, *IDP* isotoxic dose prescription, *V*~12Gy~ volume of healthy brain tissue which is irradiated to 12 Gray or more. The *solid lines* represent single-fraction PTV size-based dose prescription protocols. The *dashed line* represents a logistic regression model fitted to data of perfectly spherical GTVs

As shown in Fig. [3](#Fig3){ref-type="fig"}, for a 0 mm GTV-PTV margin, single-fraction IDP with the V~12Gy~ = 10 cm^3^ constraint offers no potential for isotoxic dose escalation in spherical GTVs with diameters \>2 cm, even when non-coplanar beams are used. For BM with a GTV diameter of 4 cm, this approach achieved an IDP dose of 14.1 Gy with a significantly lower TCP of 32% compared to the 42% that was predicted for the PTV size-based dose prescription at 15 Gy. Therefore, we have explored the potential of three-fraction and five-fraction IDP to increase the TCP, using a V~19.2~ ~Gy~ = 10 cm^3^ and V~20Gy~ = 20 cm^3^ respectively. For BM with a 4 cm diameter, using a 1 mm GTV-PTV margin and a non-coplanar beam arrangement, the predicted TCP was increased from 23% using single fraction IDP to 55 and 68% using a three-fraction IDP and five-fraction IDP respectively (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3The prescribed dose and predicted TCP for single-fraction IDP with the V~12Gy~ = 10 cm^3^ constraint as a function of the GTV diameter for coplanar and non-coplanar beam arrangements with a GTV-PTV margin of 0--2 mm and spherical GTVs. Legend: *Gy* Gray, *GTV* gross tumor volume, *TCP* tumor control probability, *IDP* isotoxic dose prescription, *V*~12Gy~ volume of healthy brain tissue which is irradiated to 12 Gray or more, *PTV* planning target volume. A GTV-PTV margin enlargement results in an increase of the PTV size. An increase in the PTV size results in different cut-offs with a PTV size-based dose prescription with 24, 21, 18, and 15 Gy. The *diamond* (*green line*), *circle* (*blue line*), and *cross* (*red line*) represent the cut-offs with dose prescriptions with GTV-PTV margins of 0, 1, and 2 mm, respectivelyFig. 4Potential of IDP to safely increase the TCP in large BM using a single, three-, and five-fraction schedule respectively. Legend: *IDP* isotoxic dose prescription, *TCP* tumor control probability, *BM* brain metastases, *V*~12Gy~ volume of healty brain tissue which is irradiated to 12 Gray or more, *V*~19.2Gy~ volume of healthy brain tissue which is irradiated to 19.2 Gray or more, *V*~20Gy~ volume of healthy brain tissue which is irradiated to 20 Gray or more. The used normal tissue constraints were a V~12Gy~ = 10 cm^3^, V~19.2~ ~Gy~ = 10 cm^3^, and V~20Gy~ = 20 cm^3^ for single, three-, and five- fraction IDP respectively

Discussion {#Sec8}
==========

In this in silico study, the potential of IDP was investigated for improving the TCP from 42% with a single fraction of 15 Gy in large BM up to 4 cm diameter, while simultaneously respecting an acceptably low NTCP limit. The concept of IDP is of clinical relevance for BM with a diameter of 2 cm or more, as the constraint of a V~12Gy~ of 10 cm^3^ for the surrounding brain tissue is exceeded with SRS independent of the GTV-PTV margin and the beam arrangement with the current PTV-based dose prescription (Fig. [1](#Fig1){ref-type="fig"}). In a large cohort of patients treated with SRS alone for a maximum of 3 BM, the median diameter of the BM was 2.3 cm, so this study is of relevance for at least half of BM patients treated with SRS in daily clinical practice \[[@CR2]\]. Despite avoiding a GTV-PTV margin and exploiting a coplanar beam arrangement, the single-fraction IDP SRS approach with the V~12Gy~ = 10 cm^3^ constraint for the nearby healthy brain tissue did not improve the predicted TCP over the standard SRS dose prescription with 15 Gy. As expected, five-fraction IDP had a better therapeutic ratio than single-fraction IDP. The predicted gain of from 32 to 73% in 1‑year TCP using five-fraction IDP instead of single-fraction IDP is significant. Such gain is especially relevant for oligometastases patients treated with curative intent in whom ablation of metastases and hence maximization of TCP is the goal. For patients with a relatively short life expectancy (for example, 6 months) treated with palliative intent, a lower 1‑year TCP could be considered acceptable. For these patients, a single-fraction approach having a relatively low 1‑year TCP may be preferred over a multiple-fraction approach for patient convenience.

To further improve the 1‑year TCP above 73%, the normal tissue constraint V~20Gy~ = 20 cm^3^ needs to be relaxed, but this may result in an unacceptably high risk of radionecrosis. Alternatively, an approach with more than five fractions could be investigated if this approach increases the therapeutic ratio. The calculated TCPs are based on the model of Wiggenraad based on single-fraction SRS data for BM, and the same model was used to calculate the TCP with five fraction SRS \[[@CR4]\]. However, a fractionated approach may be beneficial for re-oxygenation of the tumor, which may increase its radiosensitivity \[[@CR21]\]. Therefore, the calculated TCP of 73% in very large BM (e. g., with a diameter of 4 cm) may be an underestimation of a clinically observed TCP using five fraction IDP. The current TCP model includes only prescription dose as a prognostic variable, but further extension of this model with other factors such as BM volume and possibly imaging characteristics reflecting hypoxia may further improve its accuracy. However, the influence of tumor size is difficult to quantify because in many series, lower doses are prescribed for larger BM or prescribed doses vary widely. Furthermore, the model needs to be externally validated and calibrated in other patient cohorts treated with SRS for BM. Dose--volume thresholds for an acceptably low risk of radionecrosis for schemes other than single-fraction and five-fraction SRS do not exist in literature.

To exploit the full potential of IDP in SRS, it is necessary to minimize the GTV-PTV margin and to optimize the beam arrangements by increasing the setup accuracy (6 degrees of freedom couch and a robust frameless mask) \[[@CR22], [@CR23]\]. Taking into account that the risk of radionecrosis increases rapidly above 10% as the V~12Gy~ exceeds 10 cm^3^ for single-fraction SRS, it is clinically highly relevant to strive for a smaller GTV-PTV margin and to explore the feasibility of dose delivery with non-coplanar beam arrangements \[[@CR14]\]. This is supported by a recently published randomized trial demonstrating that a decrease of the GTV-PTV margin from 3 to 1 mm does not decrease the local control probability for LINAC-based SRS \[[@CR17]\]. As this study showed that there was a significantly larger V~12Gy~ in the 3 mm GTV-PTV margin group, the authors stated that a 1 mm GTV-PTV margin should be used to avoid any unnecessary risk of radionecrosis and serious risk of neurologic morbidity.

A limitation of our research is the lack of clinical validation of the models to predict TCP and NTCP. The TCP model is based on retrospective clinical studies \[[@CR4]\]. Prospective clinical validation is needed for the NTCP model by using a V~12Gy~ = 10 cm^3^ constraint for single-fraction IDP, a V~19.2~ ~Gy~ = 10 cm^3^ constraint for three-fraction IDP, and a V~20Gy~ = 20 cm^3^ constraint for five-fraction IDP \[[@CR3], [@CR14], [@CR20]\].

In the last few years, much efforts have been made to safely increase the TCP of SRS in large BM using standard dose prescription and mild hypofractionation \[[@CR24]--[@CR29]\]. However, in all these efforts the main drawback remains that a fixed dose will always result in a variety of radionecrosis risks with different sized BM. In a palliative setting of metastasized cancer patients it seems more appropriate to make the statement of "do not harm the patient". Therefore the usage of IDP with the principle of a low risk of radionecrosis with any sized BM is preferable over fixed SRS dose prescription.

In conclusion, using three-fraction or five-fraction IDP the predicted TCP can be increased safely to 55 and 68% respectively in BM with a diameter of 4 cm with a low risk of radionecrosis. Using IDP, the therapeutic ratio of SRS in large BM can be increased compared to current SRS dose prescription.

Appendix {#Sec9}
========

Fitted TCP model for 12-month local rate {#Sec10}
----------------------------------------

In Wiggenraad et al. \[[@CR4]\], a dose--response relation between the biologically effective dose of the linear-quadratic-cubic model using an α/β of 12 Gy (BED~12~) and the 12-month local control rates were constructed by eye fitting. Herein we obtained a statistical better fit by first digitizing the data points from Wiggenraad's figure \[[@CR4]\] using GraphClick software (version 3.0.2, Arizona Software) and subsequently fitting a logistic dose--response model by the maximum likelihood estimation:$$\documentclass[12pt]{minimal}
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                \begin{document}$$\textit{TCP}(D)=\frac{\textit{TCP}_{\max}}{1+\left(\frac{D_{50}}{D}\right)^{4\gamma _{50}}}$$\end{document}$$where *D* = BED~12~, *D*~50~ is the BED~12~ at 50% local control, *γ*~50~ is the normalized slope at *D*~50~, and *TCP*~max~ is the asymptotic local control rate for large *D*. The fitted dose--response graph is shown in Fig. [5](#Fig5){ref-type="fig"}.Fig. 5A fitted dose-response curve based on data from Wiggenraad et al. \[[@CR4]\]

The model parameters obtained are *D*~50~ = 28.97 Gy (95% confidence interval \[CI\]: 24.80--33.14 Gy), *γ*~50~ = 1.41 (95% CI: 0.40--2.87), and *TCP*~max~ = 86.86% (95% CI: 70.62--103.10%).
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